Fujisawa T, Yonemoto R H, Waldman S R
Jpn J Surg. 1981;11(6):406-12. doi: 10.1007/BF02469023.
Specific and nonspecific serum blocking factors (SBF) in sera from 48 breast cancer patients were examined to evaluate the correlation of SBF to the tumor burden. Specific SBF in leucocyte adherence inhibition (LAI) assay was demonstrated in 15 of 21 patients with a recurrence, in five of 11 with local or regional involvement and in 3 of 16 with no evidence of the disease (NED). The difference between patients with recurrence and with NED was significant (P less than 0.005). SBF in LAI and lymphocyte blastogenesis correlated in 29 of 48 (60%) patients (both positive 9 of 48, both negative 20 of 48). However, SBF in LAI was demonstrated in 14 of 48 (29%) patients whose sera showed no SBF in lymphocyte blastogenesis. These results indicate that SBF in LAI and lymphocyte blastogenesis are either induced or derived from breast cancer tissue. SBF in LAI correlates closely with the tumor burden, more so than do SBF in lymphocyte blastogenesis. The blocking assays have a potential use for prognostication and a guide for clinical therapy.
检测了48例乳腺癌患者血清中的特异性和非特异性血清封闭因子（SBF），以评估SBF与肿瘤负荷的相关性。在21例复发患者中的15例、11例局部或区域受累患者中的5例以及16例无疾病证据（NED）患者中的3例，在白细胞黏附抑制（LAI）试验中证实存在特异性SBF。复发患者与NED患者之间的差异具有显著性（P小于0.005）。在48例患者中的29例（60%）中，LAI试验中的SBF与淋巴细胞增殖相关（两者均为阳性的有48例中的9例，两者均为阴性的有48例中的20例）。然而，在48例患者中的14例（29%）中，其血清在淋巴细胞增殖试验中未显示SBF，但在LAI试验中显示有SBF。这些结果表明，LAI试验中的SBF和淋巴细胞增殖试验中的SBF要么是由乳腺癌组织诱导产生，要么是来源于乳腺癌组织。LAI试验中的SBF与肿瘤负荷密切相关，比淋巴细胞增殖试验中的SBF更密切。这些封闭试验在预后判断方面具有潜在用途，可为临床治疗提供指导。
